BIO3 Share Price

Open 22.75 Change Price %
High 22.75 1 Day 0.00 0.00
Low 22.55 1 Week 1.08 5.00
Close 22.70 1 Month 1.20 5.58
Volume 49304 1 Year 9.02 65.94
52 Week High 23.88
52 Week Low 12.02
BIO3 Important Levels
Resistance 2 22.89
Resistance 1 22.81
Pivot 22.67
Support 1 22.59
Support 2 22.51
ETR Germany Most Active Stocks
DBK 16.01 2.50%
DBK 16.01 2.50%
DAI 60.92 -2.65%
DAI 60.92 -2.65%
CBK 10.55 2.13%
CBK 10.55 2.13%
DTE 15.54 -0.19%
DTE 15.54 -0.19%
DTE 15.54 -0.19%
DTE 15.54 -0.19%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
SC2 14.78 18.24%
5M71 39.00 13.70%
BSL 156.50 8.91%
BSL 156.50 8.91%
BSL 156.50 8.91%
BSL 156.50 8.91%
I8R 79.34 7.07%
VSC 5.34 7.01%
VSC 5.34 7.01%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
BC8 57.85 -49.25%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
N4G 4.85 -13.08%
CFC 0.73 -9.88%
CFC 0.73 -9.88%
R3Q 0.10 -9.09%
More..

Biotest AG (ETR: BIO3)

BIO3 Technical Analysis 5
As on 24th Jul 2017 BIO3 Share Price closed @ 22.70 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 16.64 & Strong Buy for SHORT-TERM with Stoploss of 21.28 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO3 Target for July
1st Target up-side 23.7
2nd Target up-side 24.86
3rd Target up-side 26.02
1st Target down-side 20.4
2nd Target down-side 19.24
3rd Target down-side 18.08
BIO3 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO3 Address
BIO3
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO3 Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO3 ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO3 Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.